Crossmark

Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir

Crossref DOI link: https://doi.org/10.1016/j.aohep.2023.101119

Published Print: 2023-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Da Wang, Fa-

Zhou, Jing

Li, Lan-Qing

Li, Yu-Jing

Wang, Meng-Lan

Tao, Ya-Chao

Zhang, Dong-Mei

Wang, Yong-Hong

Chen, En-Qiang
License Information

Text and Data Mining valid from 2023-09-01

Text and Data Mining valid from 2023-09-01

Version of Record valid from 2023-05-30
More Information

This article is maintained by: Elsevier

Article Title: Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir

Journal Title: Annals of Hepatology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.aohep.2023.101119

Content Type: article

Copyright: © 2023 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below